卡痛(Kratom)的药理学与临床评估
本文综述了卡痛(Mitragyna speciosa)的药理学、临床效用、不良反应及滥用潜力。卡痛通过阿片受体和α-2受体激动、抗炎及抗副交感作用发挥效应,但缺乏高质量人体药理学、药代动力学及药物相互作用研究,无法对其安全性和有效性得出确切结论。
要点
- 卡痛具有阿片受体和α-2受体激动作用,并产生抗炎和抗副交感效应。
- 缺乏高质量人体药理学、药代动力学和临床数据,安全性和有效性结论不明确。
核心结论
- 卡痛通过阿片受体和α-2受体激动、抗炎及抗副交感作用发挥效应。
- 人体药理学、药代动力学和临床数据质量低,无法就安全性和有效性得出确切结论。
研究设计与样本
- 本文为综述,回顾卡痛的药理学、临床效用、不良反应和滥用潜力。
- 卡痛叶含有生物活性生物碱,包括帽柱木碱(mitragynine)。
- 未发表关于卡痛或帽柱木碱的人体药理学、药代动力学或药物相互作用研究。
主要发现
- 卡痛可用于缓解阿片戒断症状,但本身也会诱导戒断。
- 呼吸抑制不常被报告,但卡痛可引起多种不良反应且缺乏明确处理指南。
- 多项评估显示人们无法停止使用卡痛,戒断症状是问题。
- 卡痛在常规药物筛查中不出现,与其他滥用物质同服时可能不被识别。
临床怎么用
- 临床应警惕卡痛使用可能,尤其对于阿片戒断症状或无法解释的戒断表现者。
- 常规药物筛查不检测卡痛,需考虑其与其他滥用物质同服的可能性。
- 缺乏明确的不良反应处理指南,临床管理需个体化并密切监测。
局限性
- 人体药理学、药代动力学和临床数据质量低,无法得出安全性和有效性的确切结论。
- 缺乏卡痛或帽柱木碱的人体药理学、药代动力学或药物相互作用研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This article reviews the pharmacology, clinical utility, adverse effects, and abuse potential of kratom. SUMMARY: The leaves of Mitragyna speciosa contain the biologically active alkaloids of kratom. Kratom exerts opioid and α-2 receptor agonistic effects as well as antiinflammatory and parasympathetic-impeding effects. There are no published human pharmacologic, pharmacokinetic, or drug interaction studies on kratom or mitragynine, making it virtually impossible to fully understand kratom's therapeutic potential and risks and the populations most likely to benefit or experience harm from its use. Kratom has been used to ameliorate opioid withdrawal symptoms but also induces withdrawal. Human pharmacologic, pharmacokinetic, and clinical data are of low quality, precluding any firm conclusions regarding safety and efficacy. Respiratory depression has not been commonly reported, but kratom does cause a host of adverse effects without clear guidance for how they should be treated. There are numerous assessments where people have been unable to stop using kratom therapy, and withdrawal signs and symptoms are problematic. Kratom does not appear in normal drug screens and, when taken with other substances of abuse, may not be recognized. Thirty-six deaths have been attributed to kratom, and the Food and Drug Administration issued a public health warning about the substance in November 2017. CONCLUSION: Kratom exerts opioid and α-2 receptor agonistic effects as well as antiinflammatory and parasympathetic-impeding effects. Human pharmacologic, pharmacokinetic, and clinical data are of low quality, precluding any firm conclusions regarding safety and efficacy.
引用
- White CM. Pharmacologic and clinical assessment of kratom. Am J Health Syst Pharm. 2017. PMID: 29255059. doi:10.2146/ajhp161035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。